Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 13/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27712904 | 0.87 | ACHE (0.61) | ACHEHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1023071 | 0.87 | ACHE (0.61) | ACHEHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7781306 | 0.87 | ACHE (0.61) | ACHEHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12417367 | 0.87 | ACHE (0.61) | ACHEHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL25700463 | 0.85 | ACHE (0.52) | ACHEHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL180477 | 0.85 | PAOX (0.57) | ACHEEPHX1 | |
| SCHEMBL11572316 | 0.85 | PAOX (0.57) | ACHEEPHX1 | |
| SCHEMBL7570219 | 0.84 | ACHE (0.61) | ACHEHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL17225975 | 0.83 | EPHX1 (0.62) | ACHEEPHX1MEN1KMT2AFAAH | |
| SCHEMBL8971460 | 0.83 | PAOX (0.53) | ACHEHDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10588904-B2 | METAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-9433600-B2 | METAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2016-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10588904-B2 | METAP2 inhibitors and methods of treating obesity | METAP2, ADIPOR2, METAP1 | ACHE 4726/4885HDAC3 87/4885HDAC4 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.